Update on Clinical Trials in Systemic Lupus Erythematosus

Sonali Narain; Richard Furie


Curr Opin Rheumatol. 2016;28(5):477-487. 

In This Article

Targeting Interferonγ

AMG811 is a fully human IgG1 mAb that neutralizes IFNγ. Phase I trials[81,82] reported acceptable safety, tolerability and pharmacokinetic profiles. A two-part study[82] enrolling 28 patients with SLE was reported at European League Against Rheumatism (EULAR) 2015. Twenty-one patients received AMG 811 in escalating doses, but there was no significant difference in disease activity. More infections were noted in the drug group, although the rates of serious adverse events were comparable between groups. The drug has also been studied in discoid lupus patients where response to therapy could not be determined because of an increased level of clinical, histologic and molecular heterogeneity between patients at baseline.[83,84]